ATE291621T1 - Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen - Google Patents

Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen

Info

Publication number
ATE291621T1
ATE291621T1 AT97950976T AT97950976T ATE291621T1 AT E291621 T1 ATE291621 T1 AT E291621T1 AT 97950976 T AT97950976 T AT 97950976T AT 97950976 T AT97950976 T AT 97950976T AT E291621 T1 ATE291621 T1 AT E291621T1
Authority
AT
Austria
Prior art keywords
proteins
epsilon receptor
alpha chain
receptor alpha
nucleic acids
Prior art date
Application number
AT97950976T
Other languages
English (en)
Inventor
Glenn Robert Frank
James P Porter
Keith E Rushlow
Donald L Wassom
Eric R Weber
Original Assignee
Heska Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Heska Corp filed Critical Heska Corp
Application granted granted Critical
Publication of ATE291621T1 publication Critical patent/ATE291621T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT97950976T 1996-12-19 1997-12-16 Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen ATE291621T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/768,964 US5958880A (en) 1996-12-19 1996-12-19 Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
PCT/US1997/023244 WO1998027208A1 (en) 1996-12-19 1997-12-16 NOVEL FELINE Fc EPSILON RECEPTOR ALPHA CHAIN NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF

Publications (1)

Publication Number Publication Date
ATE291621T1 true ATE291621T1 (de) 2005-04-15

Family

ID=25083991

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97950976T ATE291621T1 (de) 1996-12-19 1997-12-16 Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen

Country Status (8)

Country Link
US (3) US5958880A (de)
EP (1) EP0950104B1 (de)
JP (1) JP2002500507A (de)
AT (1) ATE291621T1 (de)
AU (1) AU5384198A (de)
CA (1) CA2273855C (de)
DE (1) DE69732857D1 (de)
WO (1) WO1998027208A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof
US6057127A (en) * 1998-01-29 2000-05-02 Heska Corporation Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
AU6094100A (en) * 1999-07-13 2001-01-30 Heska Corporation Fc epsilon receptor-luminescence inducing protein chimeric nucleic acid molecules, fusion proteins and uses thereof
WO2001029078A2 (en) * 1999-10-15 2001-04-26 Heska Corporation Method for production and use of mite group 1 proteins
US6889145B1 (en) 2000-03-15 2005-05-03 Northwestern University Three-dimensional model of a Fc region of an IgE antibody and uses thereof
CA2512974A1 (en) * 2003-01-13 2004-07-29 Macrogenics, Inc. Soluble fc.gamma.r fusion proteins and methods of use thereof
US20050053615A1 (en) * 2003-07-16 2005-03-10 Best Elaine A. Variants of mite group 1 allergens for the treatment of house dust mite allergy
US7771660B2 (en) * 2004-05-04 2010-08-10 University Of North Carolina At Chapel Hill Electrophoretic interactive spectral methods and devices for the detection and/or characterization of biological particles
WO2006124866A2 (en) * 2005-05-13 2006-11-23 The Johns Hopkins University Free human serum ige immunoenzymetric assay and methods of use
WO2011034597A1 (en) * 2009-09-17 2011-03-24 Children's Medical Center Corporation Diagnostic and therapeutic uses of soluble fc-epsilon receptor i for ige-mediated disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3956752A (en) * 1975-03-12 1976-05-11 Harris Corporation Polarization insensitive lens formed of spiral radiators
EP0259615A1 (de) * 1986-08-21 1988-03-16 Kishimoto, Tadamitsu, Prof. Menschlicher Fc-epsilon-Rezeptor mit niedriger Affinität, dessen Herstellung und Reinigung
US4962035A (en) * 1987-12-01 1990-10-09 President And Fellows Of Harvard College DNA encoding IgE receptor alpha-subunit or fragment thereof
CA2000878C (en) * 1988-10-18 1999-06-29 Jean-Pierre Kinet Cdnas coding for the subunit of the high-affinity receptor for immunoglobulin e
WO1991006570A1 (en) * 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
ES2193136T3 (es) * 1991-08-14 2003-11-01 Genentech Inc Variantes de inmunoglubina para receptores especificos de fc epsilon.
JP3473973B2 (ja) * 1993-07-23 2003-12-08 株式会社先端生命科学研究所 昆虫細胞による可溶性ＩｇＥ結合受容体α鎖の製造方法
JPH0772150A (ja) * 1993-09-02 1995-03-17 Tonen Corp ＩｇＥの測定方法
US5958880A (en) * 1996-12-19 1999-09-28 Heska Corporation Feline Fc epsilon receptor alpha chain proteins and therapeutic uses thereof

Also Published As

Publication number Publication date
EP0950104A1 (de) 1999-10-20
EP0950104B1 (de) 2005-03-23
US6284881B1 (en) 2001-09-04
AU5384198A (en) 1998-07-15
DE69732857D1 (de) 2005-04-28
US5958880A (en) 1999-09-28
JP2002500507A (ja) 2002-01-08
WO1998027208A1 (en) 1998-06-25
US6103494A (en) 2000-08-15
CA2273855A1 (en) 1998-06-25
CA2273855C (en) 2003-05-27

Similar Documents

Publication Publication Date Title
DE69824597D1 (de) Ikk-beta proteine, nukleinsäuren und verfahren
NO985376D0 (no) Kinolinkarboksamider som TNF-inhibitorer og som PDA-IV inhibitorer
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
BR0210839A (pt) Sistema de recombinação, método para remover uma sequência de dna do dna cromossÈmico de uma célula ou organismo eucarióticos, organismo, cultura de célula, órgão, tecido, parte ou material de propagação transgênico, e, uso de um organismo ou de uma cultura de célula, órgão, tecido, parte ou material de propagação transgênico
DE69840387D1 (de) Nik proteine, nukleinsäure sowie verfahren
WO2000044928A3 (en) Materials and methods for the purification of polyelectrolytes
AU2002305450A1 (en) Proteomimetic compounds and methods
DE69432934D1 (de) Oligonukleotidmodulation der expression von multiwirkstoff-resistenz -assoziiertem protein
EP1135532A4 (de) Fluoreszierende proteine aus nicht-biolumineszenten arten der klasse anthozoa, gene die diese proteine kodieren und deren verwendungen
EP1629084A4 (de) Modulation der expression von c-reaktivem protein
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
ATE291621T1 (de) Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
DE69942575D1 (de) Nukleinsäuremolekül, die für die alpha-kettedes pferde-fc-epsilon-rezeptors kodieren, korrespondierende proteine und ihre verwendungen
DE69826493D1 (de) Ikk-alpha proteine, nukleinsäuren und verfahren
WO2005000335A3 (en) Use of genes differentially expressed during aging of liver for treatment and diagnosis
WO2001040313A3 (en) Feline immunoregulatory proteins, nucleic acid molecules, and uses thereof
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
ATE309270T1 (de) ßSMOOTHENEDß PROTEINE AUS WIRBELTIEREN
MXPA04005992A (es) Derivados de acido 3-fenil-2-arilalquiltiopropionico como antagonistas selectivos de ppar-alfa.
WO2004021978A3 (en) Antisense modulation of endothelial specific molecule 1 expression
WO2002102852A3 (en) Modified cd8 molecule, nucleic acid encoding said molecule, and their therapeut ic use
ATE311456T1 (de) Nucleinsäure-moleküle codierend proteine, die die adhäsion von neisseria-zellen an humane zellen vermitteln

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties